TKNO Quote, Financials, Valuation and Earnings

Puma Biotechnology, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of 16.24%. Alpha Teknova, Inc.'s return on equity of -22.95% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 91.08%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -40.27%. Given that Alpha Teknova, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Alpha Teknova, Inc. is more attractive than Puma Biotechnology, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Alpha Teknova, Inc.'s net income of -$4.3M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 6.32x versus 1.38x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of --. Alpha Teknova, Inc.'s return on equity of -22.95% beat Palatin Technologies's return on equity of --.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 91.08%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Alpha Teknova, Inc., analysts believe Palatin Technologies is more attractive than Alpha Teknova, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Palatin Technologies quarterly revenues of --. Alpha Teknova, Inc.'s net income of -$4.3M is higher than Palatin Technologies's net income of --. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 6.32x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Protara Therapeutics, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of --. Alpha Teknova, Inc.'s return on equity of -22.95% beat Protara Therapeutics, Inc.'s return on equity of -38.66%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 91.08%. On the other hand Protara Therapeutics, Inc. has an analysts' consensus of $25.00 which suggests that it could grow by 338.6%. Given that Protara Therapeutics, Inc. has higher upside potential than Alpha Teknova, Inc., analysts believe Protara Therapeutics, Inc. is more attractive than Alpha Teknova, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protara Therapeutics, Inc. has a beta of 1.385, suggesting its more volatile than the S&P 500 by 38.466%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Protara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Protara Therapeutics, Inc. quarterly revenues of --. Alpha Teknova, Inc.'s net income of -$4.3M is higher than Protara Therapeutics, Inc.'s net income of -$13.3M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Protara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 6.32x versus -- for Protara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of --. Alpha Teknova, Inc.'s return on equity of -22.95% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 91.08%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3121.35%. Given that Theriva Biologics, Inc. has higher upside potential than Alpha Teknova, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Alpha Teknova, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Alpha Teknova, Inc.'s net income of -$4.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 6.32x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.